Nova Eye Medical Ltd · ASX:EYE
Nova Eye Medical — Shareholder Meeting (November 2024)
19 slides from Nova Eye Medical's shareholder meeting presentation, Nov 21, 2024
Slide 1: Nova Eye Medical Limited (ASX:EYE) Annual General Meeting
Nova Eye Medical Limited (ASX:EYE) Annual General Meeting 21 November 2024 nova-eye.com | 1
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Nova Eye Medical Limited (ASX: EYE). While the information in this presentation has been prepared in good faith and with reasonable care, no representation or warranty, express or implied, is made as to the accuracy, adequacy or reliability of any st
Slide 3: Company Overview
Company Overview Capital Structure Share Price Chart 6,000,000 $0.35 ASX Code EYE 5,000,000 $0.30 Share Price (at 20 November 2024) $0.16 4,000,000 $0.25 Shares on Issue 229M 3,000,000 $0.20 Unlisted Options ~3.35M 2,000,000 $0.15 Market Capitalisation $36.65M 1,000,000 0 $0.10 Cash at 30 September
Slide 4: Highlights
Highlights • Strong U.S. Sales Growth • Sales increased 35% during the four months to October 31, 2024, compared to the prior corresponding period (pcp), reflecting strong market penetration by our direct sales force. • Robust Global Performance • Global sales rose 44% (including 55% in the USA) ove
Slide 5: What is Glaucoma?
What is Glaucoma? • Glaucoma is the second leading cause of blindness in the developed world (behind cataracts)(1) with no cure. • The body produces a protein rich liquid that circulates through the ocular structures to keep it healthy. • Glaucoma is a failure of the eye’s natural outflow system thr
Slide 6: Glaucoma Treatment Overview
Glaucoma Treatment Overview • Traditional medication treatment paradigm is chronic medication use which causes eye damage limiting future treatment options. Patient adherence to glaucoma medications is poor • Patients and surgeons are favouring(1) minimally invasive glaucoma surgery (MIGS) earlier i
Slide 7: iTrack Advance
7 • iTrack Advance Single-use MIGS device is redefining the treatment of glaucoma in its early stages. • Canaloplasty offers a stent-free, tissue-preserving surgical treatment for glaucoma using an injector technology. • Injector technology has enhanced our original iTrack which has now been used in
Slide 8: iTrack Advance - Angioplasty of the Ocular System
iTrack(TM) Advance - Angioplasty of the Ocular System • Clearing blockages and rejuvenating the eye’s natural outflow pathways that have been compromised by glaucoma disease. nova-eye.com | 8
Slide 9: Clinically Significant Features iTrack Advance vs Other MIGS
Clinically Significant Features iTrackTM Advance vs Other MIGS Patient Implant- Preserves Device Company Procedure Natural Outflow Pathway Population free Tissue Trabecular Schlemm’s Collector Meshwork Canal Channels iTrackTM Mild-moderate Advance Nova Eye Medical Canaloplasty glaucoma ✓ ✓ ✓ ✓ ✓ KDB
Slide 10: Nova Eye Glaucoma Surgical Device Sales Model
Nova Eye Glaucoma Surgical Device Sales Model Canaloplasty surgery has a well-established CPT1 code authorised by the USA CMS2 Eye surgeon selects Nova Eye delivers the The operating notes are submitted to Nova Eye product. product to the Facility and Medicare Administrative Contractor invoices the
Slide 11: Revenue by Geographic Region
Revenue by Geographic Region Trailing Trailing 4 months to 4 months to Growth on Growth US $000’s 12 months to 12 months to 31 Oct 23(1) 31 Oct 24(1) PCP on PCP 31 Oct 23(1) 31 Oct 24(1) USA 3,338 4,385 31% 8,033 12,419 55% Germany 435 563 29% 1,490 1,759 18% China - 360 957 1,356 42% ROW 382 318 -1
Slide 12: USA Sales 2 Years to 30 June 2024 and First 4 Months FY25
USA Sales 2 Years to 30 June 2024 and First 4 Months FY25 • Four consecutive half-year periods of growth in USA. USA sales growth FY23 to 31 October 2024 Introduction of iTrack Advance in April 2023 (H2FY23). 7,000,000 • Growth continues into the first four months of FY25. 6,000,000 • Revenue growth
Slide 13: USA Market Share Estimate - iTrack
USA Market Share Estimate - iTrack Reported revenue (US$m) Market Share +6.4% (5) $382.0m +32% +55% YoY $359.0m iTrack gaining growth (4) $200.0m market share $200m in a growing 60% US market 52.4% $152.0m 50% $150m 42.3% $124.7m +4.5% 40% 34.7% (3) $100m (2) $92.3m $77.6m 30% $74.3m 23.8% 20.7% 20.
Slide 14: USA Reimbursement Update
USA Reimbursement Update • Surgeries with iTrack continue to attract the established CPT1 reimbursement code from US Medicare (CMS). • From December 2024 MAC’s (Medicare Administrative Contractors) will reduce reimbursement payments of stents used in for combination with MIGS procedures in same pati
Slide 15: Operating results for glaucoma segment shows positive trends
Operating results for glaucoma segment shows positive trends (1) Glaucoma Segment Global Sales and EBITDA USD ‘000 H1FY23 H2 FY23 H1FY24 H2FY24 10,000 Sales global 5,698 5,575 6,673 8,565 8,000 6,000 GM 3,305 4,243 4,604 6,262 4,000 58% 76% 69% 73% 2,000 - Opex (6,057) (5,491) (6,193) (6,530) (2,000
Slide 16: Positive glaucoma operating results drive group results
Positive glaucoma operating results drive group results Sales and Group EBITDA in AUD 15,000 AU$'000's H1FY23 H2FY23 H1FY24 H2FY24 10,000 5,000 Sales glaucoma 8,315 8,346 10,062 13,096 - (5,000) Group EBITDA (loss) (2) (6,096) (3,454) (4,203) (1,781) (10,000) H1FY23 H2FY23 H1FY24 H2FY24 A$'000's Sal
Slide 17: Summary
Summary • Sustained Sales Momentum: Strong sales growth in FY24 extended into FY25, demonstrating resilience and market demand, despite temporary supply chain disruptions (now resolved). • Operational Recovery: October 2024 sales rebounded to meet growth targets, underpinned by robust adoption of th
Slide 18: Update on 2RT for Age Related Macular Degeneration
Update on 2RT for Age Related Macular Degeneration • 2RT has the potential to change the treatment paradigm for age-related macular degeneration. • To fully exploit its potential, capital is required, and the Board is seeking non- dilutive alternatives • The company remains committed to pursue sales
Slide 19: Tom Spurling Mark Flynn
Tom Spurling Mark Flynn Managing Director Investor Relations +61 8 8362 0193 +61 416 068 733 tspurling@nova-eye.com mflynn@nova-eye.com nova-eye.com | 19
Nova Eye Medical — Shareholder Meeting (November 2024) on 6ix